Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency

Xia Wu,Hui-lei Miao,Tienan Zhu,Jun Feng,Lu Zhang,Yue-ying Mao,Daobin Zhou,Xinxin Cao,Jian Li

Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency

2019

Xia Wu
Hui-lei Miao
Tienan Zhu
Jun Feng
Lu Zhang
Yue-ying Mao
Daobin Zhou
Xinxin Cao
Jian Li

Systemic immunoglobulin light-chain (AL) amyloidosis is a plasma cell disorder characterized by immunoglobulin light chain deposition in various organs and tissues [1]. One of the un-neglectable fe...

Keywords:

Cancer research
Diabetes mellitus
Immunoglobulin Light-chain Amyloidosis
Biochemistry
Factor X deficiency
Factor X Activity
Medicine
Bortezomib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations